EntreMed appoints interim CEO
This article was originally published in Scrip
The clinical-stage cancer company has appointed Dr Ken Ren as interim CEO, effective 2 April 2012. Dr Ren has years of experience in conducting global trials for multi-national pharmaceutical and biotech companies, and was also the founder and key manager of several private companies operating in the US and China in pharmaceutical development and services. The new appointment comes just months after the company announced that it had appointed Dr Wei-Wu He executive chair, and Dr Tak Mak to its board of directors.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.